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Pulmonary Arterial Hypertension
Gifty Menka, BSN, RN
• Pulmonary arterial hypertension (PAH) is characterized by 
persistently elevated pressures in the pulmonary arteries 
(Poch, 2016). 
• PAH is a rare disease with about 500 - 1000 new cases a 
year in the U.S. The prevalence of PAH is equal among all 
ethnicities and races (Raredisease.org, 2020). 
• PAH can be life-threatening with a general life expectancy 
of 5 years if left untreated or treated inadequately, making 
early diagnosis and treatment crucial for patients and 
healthcare providers (Poch, 2016).
• As a former cardiac nurse who has taken care of PAH 
patients, and witnessed how devastating the disease is 
even with treatment, I feel the need to bring awareness to 
early diagnosis and treatment. 
Otterbein University, Westerville, Ohio
 PAH is a disease that mostly affects the small resistance pulmonary arteries shown 
by intimal hyperplasia, medial hypertrophy, adventitial proliferation, localized 
thrombosis, and inflammation (Prins & Thenappan, 2016).  
 PAH can be idiopathic, hereditable, drug and toxin-induced, or associated with 
connective tissue diseases, HIV infections, portal hypertension, congenital heart 
disease, and schistosomiasis (Prins & Thenappan, 2016). 
 The gene involved in the hereditary PAH is the BMPR2 gene. The BMPR2 gene 
controls the number of cells in certain tissues. Mutation in the gene increases cell 
division or cell death leading to excessive growth of cells in the small arteries in the 
lungs (NIH, 2017).  
 The excessive growth from the BMPR2 gene mutations narrows the small pulmonary 
arteries’ diameter, which leads to resistance. To compensate for the resistance, BP in 
the pulmonary artery and the heart’s right ventricle go up to overcome the increased 
resistance (NIH, 2020). 
 There is persistent elevation in the right ventricle (RV) afterload as a result of 
pulmonary vascular resistance (PVR), which causes right ventricular hypertrophy 
(Prins & Thenappan, 2016). 
 The disease process of PAH includes pulmonary vascular dysfunction associated 
with an imbalance of vasoconstricting and vasodilating substances in the small 
pulmonary arteries. The imbalance has been shown to favor the vasoconstricting






 PAH can be challenging to diagnose due to non-specific signs 
and symptoms initially, but the following are the symptoms 





 Exertional syncope and angina is seen as the disease 
progresses
 Development of Tricuspid regurgitation
 Increased intensity of the second heart sound
 Peripheral edema, ascites, and elevated jugular venous pressure 
can develop when the right heart chambers hypertrophy, and the 
left ventricle fails.
 Pulsatile hepatomegaly
 Nursing play a huge role in educating patients and family about 
the condition. Newly diagnosed PAH patients need information 
and education regarding the disease tailored to them and given 
at the right time (Graarup, Ferrari, & Howard, 2016).
 Nurses who take care of PAH patients need to be educated on 
the disease and current therapies. The focus should be on 
proper monitoring of patients receiving treatment with 
continuous IV therapies such as Epoprostenol due to the short 
half-life of the drug (Smith, York, Kane, & Weitendorf, 2015). 
 Always have a backup IV pump, and an extra drug on the unit 
for pump malfunction or drug disconnections as an interruption 
in the drug’s flow can cause life-threatening rebound elevation in 
pulmonary vascular resistance that can lead to acute heart 
failure and death (Ricketts & Church, 2017). 
 Nurses caring for PAH patients need to monitor for complications 
such as line infections, thrombosis, and embolism (Ricketts 
&Church, 2017). 
 Make sure that patients are eating their meals as nutritional 
deficiencies have been seen with PAH (Vinke, Jansen, Witkamp, 
& Norren, 2018). 
 Nurses caring for PAH patients need to monitor them for signs 
and symptoms of RV failure (Leeper & Powell, 2019).
 Monitor oxygenation levels and start oxygen therapy for a Pao2 
of less than 60 mmHg (Leeper & Powell, 2019). 
 The nurse must report adverse medication reactions to the 
provider and give as-needed medications to reduce adverse 
reactions like nausea and diarrhea (Leeper & Powell, 2019).
 Nurses caring for PAH patients need to do a full head-to-toe 
assessment and report any changes to providers (Leeper & 
Powell, 2019). 
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Implications for Nursing Care
(Table 1. WHO functional classification of pulmonary arterial 
hypertension. (Ricketts & Church, 2017)
(Figure 2. Classification of pulmonary hypertension, WHO 2008 (modified and not exhaustive)1
(Ricketts & Church, 2017).
• PAH can be challenging to diagnose due to non-specific 
presenting symptoms (Ricketts & Church, 2017).
• The average time between the onset of symptoms and 
diagnosis of PAH ranges anywhere from 18-32 months (Prins
& Thenappan, 2016).
• Right heart catheterization is regarded as the gold standard 
for PAH diagnosis as it provides the hemodynamic data that 
defines the disease (Pristera, Musarra, Schilz, & Hoit, 2015).
• Echocardiography, although not considered the gold 
standard for the diagnosis of PAH, can be used to diagnose 
PAH. Echocardiography is also used to assess the existence 
of right ventricular (RV) or right atrial enlargement or dilation 
and cardiac causes of PAH, such as valvular heart disease, 
left ventricular dysfunction, or pericardial effusion (Leeper & 
Powell, 2019). 
• PAH is defined hemodynamically as a mean pulmonary 
arterial pressure (mPAP) greater than or equal to 25 mm Hg 
at rest (Pristera, Musarra, Schilz, & Hoit, 2015).
• There are 5 types of pulmonary hypertension (PH), according 
to the World Health Organization. They are (1) PAH, (2) PH 
due to left heart disease, (3) PH due to lung disease, or 
hypoxia, (4) chronic thromboembolic PH, and (5) PH with 
unclear multifactorial means (Pristera, Musarra, Schilz, & 
Hoit, 2015).
• The WHO recognizes 4 functional classes in PH. Functional 
class I is considered the mildest form of the disease, and 
class IV is the most severe ( Ricketts & Church, 2017). 
(Figure1 Sysol & Machado, 2018)
Significance of Pathophysiology
Diagnosis
 PAH is a complex disease that requires expert care (Ricketts & Church, 2017).
 The condition ends up affecting all the major organs of the body. The main issue with 
PAH is right-sided heart failure which then causes a more complicated clinical 
syndrome that affects multi-organ systems such as the left heart, brain, kidney, liver, 
gastrointestinal tract, skeletal muscle, endocrine, immune, and autonomic systems 
(Rosankranz, Howard, Gomberg-Maitland, & Hoeper, 2020).
 PAH is a life-threatening disease with a general life expectancy of 
5 years if left untreated or treated inadequately, making early 
diagnosis and treatment crucial for patients and healthcare 
providers (Poch, 2016).
 PAH disease-targeted therapy can only be started by doctors in 
specialist centers who specialize in treating PAH (Ricketts & 
Church, 2017).
 The initial signs and symptoms can be vague, which delays 
prompt diagnosis (Ricketts & Church, 2017).
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I Patients with pulmonary hypertension but without resulting 
limitation of physical activity. Ordinary physical activity does not 
cause dyspnea or fatigue, chest pain, or near syncope
II Patients with pulmonary hypertension resulting in slight limitation 
of physical activity. They are comfortable at rest. Ordinary physical 
activity causes undue dyspnea or fatigue, chest pain, or near
syncope
III Patients with pulmonary hypertension resulting in marked limitation 
of physical activity. They are comfortable at rest. Less than 
ordinary activity causes undue dyspnea   or fatigue, chest pain, or 
near syncope
IV Patients with pulmonary hypertension with inability to carry out 
any physical activity without symptoms. These patients manifest 
signs of right heart failure. Dyspnea and/or fatigue may even be 
present at rest. Discomfort is increased by any physical activity
